Abstract | OBJECTIVES: BACKGROUND: The benefits of paclitaxel-eluting stent (PES) implantation during primary PCI were confirmed by the long-term results of the HORIZONS-AMI trial. Whether the effects of PES are independent of age has not been reported. METHODS: Data on 3,006 patients from the HORIZONS-AMI study randomized in a 3:1 ratio to PES or bare- metal stent (BMS) in whom at least one stent was implanted were assessed. There were 2,302 (76.6%) patients <70, and 704 patients ≥70 years of age. RESULTS: At 3 years, among older patients a trend toward lower risk of major adverse cardiac events ( MACE; death from any cause, stroke, reinfarction and unplanned revascularization for ischemia) related to PES use was observed (PES vs. BMS: 18.0% vs. 21.3%; P = 0.07). There was also a trend for reduction of MACE related to PES in older patients (26.4% vs. 33.1%; P = 0.09). Both, patients <70 and ≥70 years of age treated with PES were at lower risk for ischemic target vessel revascularization. However, a higher risk of major bleeding in elderly patients treated with PES was observed (P = 0.02 for interaction between age group and PES effects). No interaction between age and stent type in terms of the risk of other clinical end points, including all-cause death, was confirmed. CONCLUSIONS: For STEMI patients undergoing primary PCI, the implantation of PES as compared with BMS reduced ischemic TVR, and this effect was independent of age.
|
Authors | Dariusz Dudek, Roxana Mehran, Artur Dziewierz, Bernhard Witzenbichler, Bruce R Brodie, Ran Kornowski, Martin Fahy, Alexandra J Lansky, Tomasz Rakowski, Jacek Legutko, Leszek Bryniarski, Gregg W Stone |
Journal | Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
(Catheter Cardiovasc Interv)
Vol. 82
Issue 6
Pg. 869-77
(Nov 15 2013)
ISSN: 1522-726X [Electronic] United States |
PMID | 23359554
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013 Wiley Periodicals, Inc. |
Chemical References |
- Cardiovascular Agents
- Paclitaxel
|
Topics |
- Age Factors
- Aged
- Angioplasty, Balloon, Coronary
(adverse effects, instrumentation, mortality)
- Cardiovascular Agents
(administration & dosage)
- Disease-Free Survival
- Drug-Eluting Stents
- Female
- Hemorrhage
(etiology)
- Humans
- Kaplan-Meier Estimate
- Male
- Middle Aged
- Myocardial Infarction
(diagnosis, mortality, therapy)
- Paclitaxel
(administration & dosage)
- Recurrence
- Risk Factors
- Stroke
(etiology)
- Time Factors
- Treatment Outcome
|